Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Lipella Pharmaceuticals Inc.

$0.1

-0.03 (-21.54%)

F 15Pipeline Score Richly Valued Pharma · Clinical
Market Cap
10.54 M
EPS
-4.11
P/E Ratio
-
Value Trade
2.67 K
SEC Financials
Q3 2025

  • Dilution Risk

    95%

  • R&D Expenses

    720.97 K

  • Total Assets

    2.35 M

  • Total Liabilities

    862.22 K

  • Equity

    1.49 M

0 %
Week
0 %
1 Month
0 %
3 Month
0 %
6 Month
0 %
5 Year
-95.8 %
All Time
Cash Data
Critical

  • Cash Position

    1.86 M

  • Monthly Burn

    425.00 K

  • Runway

    0 mo

  • Burn Trend

    Stable

  • SEC Filing

    Nov 14, 2025
Overview
Volume
25.95 K
52 Week Range
null-null
% held by Insiders
6.53 %
% held by Institutions
1.41 %
Enterprise Value
6.34 M
Total Shares
4.47 M
Short %
2.4 %
Float Shares
3.33 M
Company Description
Founded:19-12-2022

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Unlock the full Catalyst Timeline
Past FDA Catalysts & PDUFA Decisions
Date Drug Catalyst Stage Outcome Reaction Event Move % Best Trade %
2025-05-15
LP-10 (Liposomal Tacrolimus)
phase 2a data readout
Phase 2a
—
–
–
–
2025-05-15
LP-10 (Liposomal Tacrolimus)
phase 2a data readout
Phase 2a
—
–
–
–
2025-05-15
LP-10 (Liposomal Tacrolimus)
phase 2a data readout
Phase 2a
—
–
–
–
Unlock 1 more historical catalysts
Drug Pipeline Intelligence
F15
Pipeline Score
$0M
Pipeline Value
Richly Valued
Valuation Signal
3
Drugs Scored
0.0x
rNPV / MCap
Top 11%
Micro Cap
(rank 822 of 923)
Percentile Rank
Lipella Pharmaceuticals Inc. has significant pipeline risk (15/100), with $144M risk-adjusted pipeline value, led by LP-10 in Hemorrhagic Cystitis (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
LP-10
Small molecule		Hemorrhagic CystitisPhase 2NCT0312912614% $86M COMPLETED 13 - -Sep 29, 2023 -Dec 11, 2023
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
LP-10
oral lichen planus
Phase 2a
2025-09-18

safety profile: met its primary safety endpoint; efficacy outcomes: statistically significant improvements across all efficacy measures at the 4-week timepoint; dose groups: All three dose groups (0.25 mg, 0.5 mg, and 1.0 mg) demonstrated statistically significant improvements at Week 4 (all p<0.05); IGA: showed clear reductions in ulceration and erythema scores

Read More

Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen Planus

Read More
LP-10
oral lichen planus
Phase 2a
2025-09-18

safety profile: met its primary safety endpoint; efficacy outcomes: statistically significant improvements across all efficacy measures at the 4-week timepoint; dose groups: All three dose groups (0.25 mg, 0.5 mg, and 1.0 mg) demonstrated statistically significant improvements at Week 4 (all p<0.05); IGA: showed clear reductions in ulceration and erythema scores

Read More

Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen Planus

Read More
LP-10
oral lichen planus
Phase 2a
2025-09-18

safety profile: met its primary safety endpoint; efficacy outcomes: statistically significant improvements across all efficacy measures at the 4-week timepoint; dose groups: All three dose groups (0.25 mg, 0.5 mg, and 1.0 mg) demonstrated statistically significant improvements at Week 4 (all p<0.05); IGA: showed clear reductions in ulceration and erythema scores

Read More

Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen Planus

Read More
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in LIPO
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
LIPO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How LIPO ranks across every disease it competes in
Competitive Position is a premium feature
See how LIPO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial